13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001633313
Total reported value
$11.1B
$11.1B
33 檔
44.5%
During the Q4 2025 filing period, Avoro Capital Advisors LLC (CIK: 0001633313) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $11.1B across 33 reported positions.
In Q4 2025, Avoro Capital Advisors LLC displayed an active expansion posture, initiating 11 new positions and adding to 10 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including UTHR, ASND, MDGL) accounted for 44.5% of total reported equity market value during Q4 2025.
Top New Position Initiated
CELC
市值: $310.3M
Top Position Liquidated / Trimmed
MERUS N V
前期市值: $333.5M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | Stock-Healthcare | 12.48% | -1.92% | +17.27% | |
| 2 | ASND | Ascendis Pharma A/S | Stock-Other | 10.72% | -11.39% | EXIT | |
| 3 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 10.35% | -0.52% | -1.39% | |
| 4 | ARGX | Argenx Se - Adr | Stock-Healthcare | 8.18% | +1.15% | — | |
| 5 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 7.00% | +2.30% | +4.00% | |
| 6 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 6.93% | +1.71% | -2.52% | |
| 7 | KYMR | Kymera Therapeutics Inc | Stock-Other | 5.72% | +1.58% | +17.71% | |
| 8 | GPCR | Structure Therapeutics Inc | Stock-Other | 4.48% | +0.05% | +21.27% | |
| 9 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 3.87% | — | -28.65% | |
| 10 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.58% | -4.47% | EXIT | |
| 11 | CELC | Celcuity Inc | Stock-Other | 3.05% | -0.63% | — | |
| 12 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 3.02% | -4.84% | EXIT | |
| 13 | VERA | Vera Therapeutics Inc | Stock-Other | 2.93% | -0.12% | -5.17% | |
| 14 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 2.52% | — | — | |
| 15 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.39% | -0.18% | +0.45% | |
| 16 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.73% | -2.95% | EXIT | |
| 17 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.70% | +1.62% | — | |
| 18 | QURE | uniQure N.V. | Stock-Other | 1.45% | +1.82% | +38.38% | |
| 19 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.32% | -0.76% | EXIT | |
| 20 | OCUL | Ocular Therapeutix Inc | Stock-Other | 1.29% | +0.08% | +5.15% | |
| 21 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.17% | +0.51% | — | |
| 22 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 0.66% | — | — | |
| 23 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 0.51% | — | — | |
| 24 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.46% | +0.12% | — | |
| 25 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.40% | — | — | |
| 26 | ALKS | Alkermes plc | Stock-Healthcare | 0.39% | -0.42% | EXIT | |
| 27 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.37% | — | — | |
| 28 | SEPN | Septerna Inc | Stock-Other | 0.37% | +0.08% | — | |
| 29 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.32% | -0.05% | — | |
| 30 | MNKD | Mannkind CORP | Stock-Other | 0.25% | -0.05% | EXIT | |
| 31 | GHRS | GH Research PLC | Stock-Other | 0.22% | +0.18% | — | |
| 32 | INCY | Incyte CORP | Stock-Healthcare | 0.13% | — | — | |
| 33 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 0.07% | +0.02% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | GPCR | Structure Therapeutics Inc | +2.6% | +21.27% | Add |
| 2 | ARWR | Arrowhead Pharmaceuticals In | +2.1% | -2.52% | Trim |
| 3 | UTHR | United Therapeutics CORP | +1.5% | +17.27% | Add |
| 4 | KYMR | Kymera Therapeutics Inc | +1.1% | +17.71% | Add |
| 5 | KRYS | Krystal Biotech Inc | +0.7% | +4.00% | Add |
| 6 | VERA | Vera Therapeutics Inc | +0.6% | -5.17% | Trim |
| 7 | TSHA | Taysha Gene Therapies Inc | +0.3% | — | Unchanged |
| 8 | 260 | Centessa Pharmaceuticals-adr | +0.2% | +34.67% | Add |
| 9 | ORKA | Oruka Therapeutics Inc | +0.1% | — | Unchanged |
| 10 | SEPN | Septerna Inc | 0% | — | Unchanged |
| 11 | WHWK | Whitehawk Therapeutics Inc | — | — | Unchanged |
| 12 | MNKD | Mannkind CORP | -0.1% | -0.55% | Trim |
| 13 | OCUL | Ocular Therapeutix Inc | -0.3% | +5.15% | Add |
| 14 | XENE | Xenon Pharmaceuticals Inc | -0.4% | +0.45% | Add |
| 15 | RNAGBP | Avidity Biosciences Inc | -0.4% | -28.65% | Trim |
| 16 | ALKS | Alkermes plc | -0.5% | -37.50% | Trim |
| 17 | MDGL | Madrigal Pharmaceuticals Inc | -0.5% | -1.39% | Trim |
| 18 | APLSUSD | Apellis Pharmaceuticals Inc | -0.6% | — | Unchanged |
| 19 | SLNOEUR | Soleno Therapeutics Inc | -0.9% | +12.50% | Add |
| 20 | ARGX | Argenx Se - Adr | -1.3% | — | Unchanged |
| 21 | QURE | uniQure N.V. | -1.9% | +38.38% | Add |
| 22 | ASND | Ascendis Pharma A/S | -2.4% | +1.00% | Add |
| 23 | ✓ | Merus N V | — | EXIT | Sold out |
| 24 | CELC | Celcuity Inc | — | NEW | New buy |
| 25 | XBI | Ss Spdr S&p Biotech ETF | — | NEW | New buy |
| 26 | AKRO | Akero Therapeutics Inc | — | EXIT | Sold out |
| 27 | 430 | Terns Pharmaceuticals Inc | — | NEW | New buy |
| 28 | RVMD | Revolution Medicines Inc | — | NEW | New buy |
| 29 | TRML | Tourmaline Bio Inc | — | EXIT | Sold out |
| 30 | AM6 | Amicus Therapeutics Inc | — | EXIT | Sold out |
| 31 | ETNBGBP | 89bio Inc | — | EXIT | Sold out |
| 32 | BRD1EUR | Mind Medicine Mindmed Inc | — | NEW | New buy |
| 33 | PTCT | Ptc Therapeutics Inc | — | NEW | New buy |
| 34 | VRDN | Viridian Therapeutics Inc | — | NEW | New buy |
| 35 | APGE | Apogee Therapeutics Inc | — | NEW | New buy |
| 36 | LXEO | Lexeo Therapeutics Inc | — | NEW | New buy |
| 37 | GHRS | GH Research PLC | — | NEW | New buy |
| 38 | MLTX | Moonlake Immunotherapeutics | — | EXIT | Sold out |
| 39 | INCY | Incyte CORP | — | NEW | New buy |
| 40 | BCRX | Biocryst Pharmaceuticals Inc | — | EXIT | Sold out |
| 41 | TNGX | Tango Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Avoro Capital Advisors LLC reported a total U.S. public equity portfolio value of $11.1B across 33 disclosed positions in Q4 2025.
During Q4 2025, Avoro Capital Advisors LLC's top holdings by market value included UTHR (12.5%)、ASND (10.7%)、MDGL (10.3%). The largest single position, UTHR, represented 12.5% of total portfolio value.
In Q4 2025, Avoro Capital Advisors LLC made 35 total portfolio adjustments, initiating 11 new buys, adding to 10 positions, trimming 6 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.